[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-339649-105":59,"doc-detail-339649-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","targeting-cancer-and-immune-cell-metabolism-with-the-complex-i-inhibitors-metformin-and-iacs-010759","Targeting cancer and immune cell metabolism with the complex I inhibitors metformin and IACS-010759","","Metformin and IACS-010759 are two distinct antimetabolic agents targeting mitochondrial complex I. The review highlights how mitochondrial metabolism and oxidative phosphorylation (OXPHOS) create vulnerabilities in cancer cells while also shaping tumor microenvironment immunometabolism. It summarizes evidence for direct antitumor effects and immunomodulatory actions supported by preclinical in vitro and in vivo studies, then contrasts encouraging observational results with less favorable clinical trial outcomes. For IACS-010759, major adverse effects drive a shift toward glycolysis and elevated lactate concentrations, guiding future trial directions.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/targeting-cancer-and-immune-cell-metabolism-with-the-complex-i-inhibitors-metformin-and-iacs-010759/339649/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/targeting-cancer-and-immune-cell-metabolism-with-the-complex-i-inhibitors-metformin-and-iacs-010759/339649.png","ImageObject",300,407,{"name":92,"@type":93},"Aria","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-10","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",17,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"How do metformin and IACS-010759 act on mitochondrial metabolism?","Question",{"text":113,"@type":114},"Both target mitochondrial complex I, but metformin is an established antidiabetic drug that mildly inhibits complex I, while IACS-010759 is a new potent complex I inhibitor. Their shared mechanism connects mitochondrial metabolism to cancer vulnerability.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"What antitumor and immune-related effects are described for these drugs?",{"text":118,"@type":114},"The text presents evidence of direct impact on cancer cells and immunomodulatory effects. Promising antitumoral actions are supported by preclinical in vitro and in vivo studies across diverse cancers.",{"name":120,"@type":111,"acceptedAnswer":121},"What were the key differences between observational and trial outcomes for metformin and IACS-010759?",{"text":122,"@type":114},"Observational epidemiologic studies on metformin were encouraging, but actual trial results were not as expected. IACS-010759 showed major adverse effects, leading to a metabolic shift to glycolysis and higher lactic acid concentrations.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},339649,1790168992,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":46,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":31,"preview_page_count":19,"preview_urls":145},2336464648322,"https://ap-avatar.wpscdn.com/avatar/2200025388227c56fec?_k=1778556882303663488","Targeting cancer and immune cell metabolism with the complex I inhibitors metformin and IACS-010759  \nMarc Pujalte-Martin 1,2,3 , Amine Bela€ıd1,2,3, Simon Bost2,3, Michel Kahi 1,2,3, Pascal Peraldi 1,2,3, Matthieu Rouleau2,3,4, Nathalie M. Mazure 1,2,3 and Frdric Bost 1,2,3   \n1 Inserm U1065, Centre Mditerranen de Mdecine Molculaire (C3M), Nice, France  \n2 Equipe Labellise Ligue Nationale Contre le Cancer  \n3 Facult de Mdecine, Universit C^ote d’Azur, Nice, France  \n4 CNRS UMR7370, LP2M, Nice, France  \nKeywords  \ncancer; clinical trial; IACS-010759;  \nimmunometabolism; metformin; microenvironment  \nCorrespondence  \nF. Bost, Inserm U1065, Centre Mditerranen de Mdecine Molculaire (C3M), 151 route de St Antoine de Ginestiere 06200, Nice, France.  \nE-mail: frederic. bost@univ-cotedazur.fr  \nMarc Pujalte-Martin and Amine Bela€ıd contributed equally as co-ﬁrst authors to this article.  \nNathalie M. Mazure and Frdric Bost contributed equally as co-senior authors to this article.  \n(Received 16 August 2023, revised 15 November 2023, accepted 29 December 2023, available online 12 January 2024)  \ndoi:10 . 1002/1878-0261 .13583  \nMetformin and IACS-010759 are two distinct antimetabolic agents. Metformin, an established antidiabetic drug, mildly inhibits mitochondrial complex I, while IACS-010759 is a new potent mitochondrial complex I inhibitor. Mitochondria is pivotal in the energy metabolism of cells by providing adenosine triphosphate through oxidative phosphorylation (OXPHOS) . Hence, mitochondrial metabolism and OXPHOS become a vulnerability when targeted in cancer cells. Both drugs have promising antitumoral effects in diverse cancers, supported by preclinical in vitro and in vivo studies. We present evidence of their direct impact on cancer cells and their immunomodulatory effects. In clinical studies, while observational epidemiologic studies on metformin were encouraging, actual trial results were not as expected. However, IACS-01075 exhibited major adverse effects, thereby causing a metabolic shift to glycolysis and elevated lactic acid concentrations. Therefore, the future outlook for these two drugs depends on preventive clinical trials for metformin and investigations into the plausible toxic effects on normal cells for IACS-01075 .  \n1. Introduction  \nSince Warburg’s pioneering work, it has been wellestablished that cancer cells exhibit distinct metabolism compared with normal cells [1] . Warburg initially proposed that cancer cells preferentially rely on glycolysis,  \neven in the presence of oxygen (aerobic glycolysis), to synthetize adenosine triphosphate (ATP) . He also believed that cancer cells had dysfunctional mitochondria. However, current understanding afﬁrms that cancer cells have functional mitochondria, utilizing them asa primary energy source and adapting their metabolism  \nAbbreviations  \nADP, adenosine diphosphate; AMPK, AMP-activated protein kinase; ATP, adenosine triphosphate; DC, dendritic cells; DLBCL, diffuse large B-cell lymphoma; ETC, electron transport chain; FAO, fatty acid oxidation; HIF, hypoxia-inducible factor; LDH, lactate dehydrogenase; ND1, NADH dehydrogenase 1; NRF2, nuclear factor erythroid 2-related factor 2; OS, overall survival; OXPHOS, oxidative phosphorylation; PFS, progression-free survival; TAM, tumor-associated macrophages; TAN, tumor-associated neutrophils; TCA, tricarboxylic acid cycle; TME, tumor microenvironment.  \nMolecular Oncology 18 (2024) 1719–1738 ª 2024 The Authors. Molecular Oncology published by John Wiley & Sons Ltd on behalf of 1719  \nFederation of European Biochemical Societies.  \nThis is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.  \nComplex I inhibitors, cancer and immunometabolism M. Pujalte-Martin et al.  \nto changes in the tumor microenvironment (TME) . In response to low oxygen (hypoxia), limited nutrient availabil","cbCail9EjmvJ3Qbu","https://ap.wps.com/l/cbCail9EjmvJ3Qbu","pdf",1093099,"English","# Introduction\n## Mitochondria empower cells to convert nutrients into energy\n## Targeting complex I with metformin and IACS-010759","[{\"question\":\"How do metformin and IACS-010759 act on mitochondrial metabolism?\",\"answer\":\"Both target mitochondrial complex I, but metformin is an established antidiabetic drug that mildly inhibits complex I, while IACS-010759 is a new potent complex I inhibitor. Their shared mechanism connects mitochondrial metabolism to cancer vulnerability.\"},{\"question\":\"What antitumor and immune-related effects are described for these drugs?\",\"answer\":\"The text presents evidence of direct impact on cancer cells and immunomodulatory effects. Promising antitumoral actions are supported by preclinical in vitro and in vivo studies across diverse cancers.\"},{\"question\":\"What were the key differences between observational and trial outcomes for metformin and IACS-010759?\",\"answer\":\"Observational epidemiologic studies on metformin were encouraging, but actual trial results were not as expected. IACS-010759 showed major adverse effects, leading to a metabolic shift to glycolysis and higher lactic acid concentrations.\"}]","Targeting cancer and immune cell metabolism with the complex I inhibitors metformin and IACS-010759 | PDF",1790031392,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/12e7dab1a7c1f56b70b2dad0a560906f.webp",983,1291,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b46d6fafa2cec6379a18bf0f45329906.webp",982,1290,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9912df7a77e3ca71bbf435522b342248.webp",981,1289,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b7289564bf4ff3c628d49c47f82eaea6.webp",980,1287]